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Diagnostic systems for Lassa fever (LF), a viral hemorrhagic fever caused by Lassa virus (LASV), such as 
enzyme immunoassays for the detection of LASV antibodies and LASV antigens, were developed using the 
recombinant nucleoprotein (rNP) of LASV (LASV-rNP). The LASV-rNP was expressed in a recombinant 
baculovirus system. LASV-rNP was used as an antigen in the detection of LASV-antibodies and as an 
immunogen for the production of monoclonal antibodies. The LASV-rNP was also expressed in HeLa cells by 
transfection with the expression vector encoding cDNA of the LASV-NP gene. An immunoglobulin G enzyme- 
linked immunosorbent assay (ELISA) using LASV-rNP and an indirect immunofluorescence assay using 
LASV-rNP-expressing HeLa cells were confirmed to have high sensitivity and specificity in the detection of 
LASV-antibodies. A novel monoclonal antibody to LASV-rNP, monoclonal antibody 4A5, was established. A 
sandwich antigen capture (Ag-capture) ELISA using the monoclonal antibody and an anti-LASV-rNP rabbit 
serum as capture and detection antibodies, respectively, was then developed. Authentic LASV nucleoprotein in 
serum samples collected from hamsters experimentally infected with LASV was detected by the Ag-capture 
ELISA. The Ag-capture ELISA specifically detected LASV-rNP but not the rNPs of lymphocytic choriomen­
ingitis virus or Junin virus. The sensitivity of the Ag-capture ELISA in detecting LASV antigens was compa­
rable to that of reverse transcription-PCR in detecting LASV RNA. These LASV rNP-based diagnostics were 
confirmed to be useful in the diagnosis of LF even in institutes without a high containment laboratory, since 
the antigens can be prepared without manipulation of the infectious viruses.
Lassa fever (LF) is a viral hemorrhagic fever caused by Lassa 
virus (LASV), an Old World arenavirus. Many cases of LF 
occur in western Africa in countries such as Guinea, Sierra 
Leone, and Nigeria (7, 23, 27, 29-31). It is thought that LASV 
infects tens of thousands of humans annually and causes hun­
dreds to thousands of deaths (34). Humans become infected 
through contact with infected excreta, tissue, or blood from the 
peridomestic rodent, Mastomys natalensis, the reservoir host of 
LASV (34). LASV can be transmitted to other humans via 
mucosal or cutaneous contact or through nosocomial contam­
ination (27). More than 20 imported cases of LF have been 
reported outside the endemic region in areas such as the 
United States, Canada, Europe, and Japan (1, 2,13,15,18, 24, 
25). Recently, the potential for the use of hemorrhagic fever 
viruses, including LASV, as a biological weapon has been em­
phasized (5, 6). Therefore, the development of diagnostic sys­
tems for LF is important even in countries free from LF out­
breaks to date.
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Manipulation of infectious LASV is necessary for the detec­
tion of specific antibodies. However, a high-containment lab­
oratory (biosafety level 4 [BSL-4]) is required for handling 
infectious LASV and, therefore, the preparation of LASV 
antigens cannot be implemented in institutes without a BSL-4 
facility. Within this framework, it is important to develop sen­
sitive and specific diagnostic systems for LF that eliminate the 
need for the manipulation of infectious LASV. In the present 
study, the recombinant nucleoprotein (rNP) of LASV (LASV- 
rNP) was expressed and evaluated for its ability to detect 
LASV antibodies. LASV-rNP-based enzyme-linked immu­
nosorbent and indirect immunofluorescence assays (ELISA 
and UFA) were developed. Furthermore, novel monoclonal 
antibodies to LASV-rNP were generated and used in combi­
nation with the recombinant antigen to develop an LASV 
antigen (nucleoprotein) capture ELISA. The present study 
presents an alternative strategy to develop diagnostic systems 
without handling infectious LASV.
MATERIALS AND METHODS
Cells. A HeLa cell line was cultured in the Eagle minimum essential medium 
supplemented with 10% fetal bovine serum and the antibiotics penicillin G and 
streptomycin (MEM-10FBS). Tn5 insect cells were used for the expression of the 
rNPs of arenaviruses (LASV, lymphocytic choriomeningitis virus [LCMVJ, and 
Junin virus [JUNV]) in a baculovirus system. The Tn5 insect cells were cultured 
as reported previously (38).
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Viruses. LASV (strain AV), which was isolated from an imported case of LF 
to Germany from West Africa, was used (13). The experimental process that 
required manipulation of infectious LASV was carried out in the BSL-4 labora­
tory in the P4 laboratory, INSERM, Lyon, France. Mopeia virus (MOPV), which 
belongs to the family Arenaviridae, genus Arenavirus, was also used. Recombinant 
NPs of LCMV (26) and JUNV (11), designated LCMV-rNP and JUNV-rNP, 
respectively, were also expressed in a baculovirus system and used in the study. 
A baculovirus (Ac-AP). which lacks polyhedrin expression, was used as a control 
virus (26). The virus titer of LASV in serum samples was determined by using a 
focus-forming unit (FFU) assay as described previously (3).
Sera. Four human serum samples—three samples serially collected from one 
patient with LF and one additional sample from another patient with LF—and 
ninety-six human sera collected from Japanese subjects with no history of travel 
to areas where LF is endemic were used as positive and negative controls, 
respectively. The patient with LF, from whom three serial serum samples were 
collected, was the first case of LF to be imported in Japan in 1987 (15). The other 
human serum sample was provided from the Special Pathogens Branch, National 
Center for Infectious Diseases, Centers for Disease Control and Prevention, 
Atlanta, GA.
Serum samples collected from five monkeys (Macaca fascicularis) subcutane­
ously infected with LASV strain AV at 103 FFU (two monkeys) or 107 FFU 
(three monkeys) and those collected from four monkeys with mock infection 
were also used. The serum samples used in the study were collected at 4 to 5 
weeks postchallenge.
Five hamsters were subcutaneously infected with 103 FFU of LASV, strain 
AV, and blood was drawn on days 0, 4,11, and 16 postinfection, taking the day 
on which the virus was inoculated as day 0. Serum fractions of the collected blood 
specimens were separated and tested for LASV antigen by antigen capture 
(Ag-capture) ELISA and reverse transcription-PCR (RT-PCR).
Rabbit sera (polyclonal antibodies) were raised against LASV-rNP, LCMV- 
rNP, and JUNV-rNP by immunization of rabbits with the purified LASV-rNP, 
LCMV-rNP, and JUNV-rNP, respectively, in the form of a mixture with the 
adjuvant, Inject Alum (Pierce). Rabbits were immunized with sufficient amount 
of the purified nucleoproteins of each virus three times with an interval of 2 
weeks. After confirmation of the increased titer, >10,000 times as determined by 
indirect immunofluorescence assay, which was developed in the present study, 
blood was drawn from the rabbits, and the serum fraction was used in the present 
study.
Recombinant baculovirus. In order to construct the transfer vector, a cDNA 
clone of NP from LASV strain Josiah was used. The cDNA was kindly provided 
by J. B. McCormick, former Director of the Special Pathogens Branch, National 
Centers for Infectious Diseases, Centers for Disease Control and Prevention. 
The complete nucleotide sequence of the NP gene is registered in GenBank 
under the accession number NC_004296. The DNA of the LASV-NP was am­
plified by PCR from the source using the primers LAS-NfB (5'- GT GG AT CCA 
ACACAACAATCTGG-3'; the BamHI restriction site is underlined) and LAS- 
NrB (5'-CCGGATCCATTTACAGAACGACTC-3T The PCR conditions were 
the same as previously reported (38). The 1,743-bp amplification product was 
digested with BamHI and subcloned into the BamHI site of pQE32 vector DNA 
(QIAGEN GmbH, Hilden, Germany) to construct pQE32-LASV-NP. The in­
serted LASV-NP DNA was sequenced by using appropriate primers with an ABI 
Prism 310 genetic analyzer (PE Applied Biosystems, Foster City, CA) and con­
firmed to be in proper orientation downstream the promoter and identical to the 
original sequence. The DNA fragment of LASV-NP with a histidine (His) tag 
was isolated from the plasmid, pQE32-LASV-NP, by digestion with EcoRI and 
Hindlll. It was then blunt repaired with Klenow enzyme and ligated into the 
blunt-ended BamHI site of pAcYMl (26). The resulting recombinant transfer 
vector with the correct orientation with respect to the polyhedrin promoter 
was constructed (pACYMl-His-LASV-NP). Tn5 insect cells were transfected 
with mixtures of purified Autographa californica nuclear polyhedrosis virus 
(AcMNPV) DNA and pAcYMl-His-LASV-NP according to the procedures 
described by Kitts et al. (20), with the modification of Matsuura et al. (26). 
Recombinant baculovirus was then isolated. The baculovirus, which expressed 
His-tagged LASV-rNP (His-LASV-rNP), was designated Ac-His-LASV-NP.
The baculovirus, Ac-LCMV-NP, which expressed LCMV-rNP, was used in the 
study (26).
The recombinant baculovirus that expressed JUNV-rNP, Ac-JUNV-NP, was 
generated as follows. The gene encoding the NP of JUNV (strain MC2) was 
reconstructed from cloned cDNA. The nucleotide sequence of the interest gene 
was deposited in GenBank under accession number DI0072 (12). A complete NP 
gene with the initiation and stop codons amplified by PCR using appropriate 
primers, which possessed BamHI restriction sites. The entire DNA product of 
JUNV-NP was digested with BamHI and ligated into the transfer vector
LASV-rNP1 (1-100 aa)
LASV-rNP2 (91-190 aa)
LASV-rNP3 (181-280 aa)
LASV-rNP4 (271-370 aa)
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FIG. 1. Schematic representation of truncated LASV-rNP ex­
pressed as a form of GST fusion protein in E. coli transformed with the 
corresponding expression vector. The description “LASV-NP1-6” in 
the middle portion of the figure indicates full-length LASV-rNP.
pAcUW2B (28). Clones containing the insert in the correct orientation were 
selected, and the plasmid DNA was used for cotransfection in Sf21 cells with a 
polyhedrin-positive AcMNPV DNA, and the supernatant culture was screened 
for a polyhedrin-negative phenotype by plaque assay (19). Finally, recombinant 
baculovirus clones overexpressing JUNV-rNP were obtained after three succes­
sive plaque purifications. One of them, designated AcNMPV-Jun-N'122, was 
used in the present study and is referred to hereafter as Ac-JUNV-NP.
Expression and purification of His-LASV-rNP, LCMV-rNP, and JUNV-rNP. 
Tn5 cells infected with Ac-His-LASV-NP were incubated at 26°C for 72 h. The 
cells were then washed twice with cold phosphate-buffered saline (PBS) solution. 
A preliminary study demonstrated that most of the Tn5 cellular proteins were 
solubilized in PBS containing 2 M urea (PBS-2 M urea) but that the His-LASV- 
rNP was insoluble and that the LASV-rNP could be solubilized in PBS contain­
ing 8 M urea (PBS-8 M urea). Therefore, the Tn5 cells infected with Ac-His- 
LASV-NP were first suspended in PBS-2 M urea. After the centrifugation of the 
cell suspensions at 15,000 X g for 10 min, the pellet fractions were collected and 
then were solubilized in PBS-8 M urea. After the centrifugation of the samples, 
the supernatant fractions were used as the purified antigens. LCMV-rNP and 
JUNV-rNP showed dissolution characteristics in urea similar to those of His- 
LASV-rNP; therefore, LCMV-rNP and JUNV-rNP were also fractioned in the 
same way as the His-LASV-rNP. The control antigen was produced from Tn5 
cells infected with Ac-AP in the same manner as that for the positive antigens. 
The His-LASV-rNP was also purified by using the Ni2+ column purification 
method as reported previously (38). The source for His-LASV-rNP-purification 
was the supernatant fraction of the PBS-8 M urea-treated Tn5 cells infected with 
Ac-His-LASV-NP after sufficient dilution with PBS in order to reduce the urea 
concentration.
SDS-PAGE. The expression and purification efficiency of His-LASV-rNP, 
LCMV-rNP, and JUNV-rNP were analyzed on sodium dodecyl sulfate-poly- 
acrylamide gel electrophoresis (SDS-PAGE) gels (12% polyacrylamide) after 
staining with Coomassie blue.
Establishment of MAbs. Monoclonal antibodies (MAbs) were generated as 
previously described (32, 41). BALB/c mice were immunized with purified His- 
LASV-rNP in the present study. Isotypes of the MAbs were determined by using 
a mouse MAb isotyping kit (Life Technologies).
Expression of truncated NPs of LASV. In order to determine the epitope of 
the MAbs to the His-LASV-rNP, truncated LASV-rNPs were expressed as a 
form of fusion protein with glutathione S-transferase (GST) as shown in Fig. 1. 
The DNA corresponding to each of the truncated NP fragments was amplified 
with the designed primers. The amplified DNA was subcloned into the BamHI 
and EcoRI cloning sites of plasmid pGEX-2T (Amersham Pharmacia Biotech, 
Buckinghamshire, England). Each insert was sequenced and confirmed to be in 
the correct frame and identical to the original sequence. The GST-tagged nu­
cleoprotein fragments were expressed in an Escherichia coli BL21 system.
Western blotting. The MAbs were tested for reactivity to His-LASV-rNP and 
its fragments by Western blotting as reported previously (17, 32, 41).
Pepscan analyses. ELISA was performed as reported previously with the 
purified rNP or partial nucleoprotein peptides as the antigen (33). The peptides
Downloaded from http://cvi.asm
.org/ on August 23. 2019 by guest
1184 SAIJO ET AL. Clin. Vaccine Immunol.
(A) (B)
2M urea 8M urea
FIG. 2. SDS-PAGE analyses of the purification of His-LASV-rNP 
using the Ni2' column purification method (A) and of the semipuri­
fication strategy based on the hydrophobic property of arenavirus 
nucleoproteins (B). The supernatant fractions of the Ac-AP-, Ac-His- 
LASV-NP-, Ac-LCMV-NP-, or Ac-JUNV-NP-infected Tn5 cells 
treated with PBS-2 M urea (B, left part) are shown. The pellet frac­
tions of these cells treated with PBS-2 M urea were further solubilized 
with PBS-8 M urea (B, right part).
were shifted by 1 amino acid (aa), with a consecutive overlap of 9 aa to cover the 
entire LASV-NP1 (aa 1 to 100) and LASV-NP5 (aa 361 to 460) fragments. 
Linear epitopes on the NP were determined by using Pepscan (Chiron Technol­
ogies, Clayton, Australia) according to the manufacturer’s instructions. Ninety- 
six peptides were prepared as 14-aa biotinylated peptides, including a 4-aa spacer 
sequence (SGSG) at the amino-terminal end, according to each of the amino 
acid sequences of the LASV-rNPl and LASV-rNP5 of the LASV Josiah strain. 
The methods were previously described in detail (33).
IgG-ELISA. Immunoglobulin G (IgG)-ELISA was performed as previously 
described except for the antigen preparation (38, 39). Briefly, ELISA plates 
(96-well type plate, Pro-Bind; Falcon; Becton Dickinson Labware, Franklin 
Lakes, NJ) were coated with the predetermined optimal quantity of purified 
His-LASV-rNP, LCMV-rNP, or JUNV-rNP (approximately 100 n^well) at 4°C 
overnight. Then, each well of the plates was inoculated with 200 |xl of PBS 
containing 5% skim milk and 0.05% Tween 20 (M-T-PBS), followed by incuba­
tion for 1 h for blocking. The plates were washed three times with T-PBS and 
then inoculated with the test samples (100 pl/well), which were diluted fourfold 
from 1:100 to 1:6,400 with M-T-PBS. After a 1-h incubation period, the plates 
were washed three times with T-PBS, and then the plates were inoculated with 
goat anti-human IgG antibody labeled with HRPO (1:1,000 dilution; Zymed 
Laboratory). After a further 1-h incubation period, the plates were washed and 
100 pd of ABTS [2,2'azinobis(3-ethylbenzthiazolinesulfonic acid)] solution 
(Roche Diagnostics, Mannheim, Germany) was added to each well. The plates 
were incubated for 30 min at room temperature, and optical density was at 405 
nm (OD405) was measured against a reference of 490 nm. The adjusted OD405 
was calculated by subtracting the OD of the negative antigen-coated wells from 
that of the corresponding wells. The means and standard deviations were calcu­
lated from the 96 control sera. The cutoff value for the assay was defined as the 
mean plus 3 standard deviations.
Immunofluorescence. The pQE32-LASV-NP was digested with BamHI, and 
the insert was subcloned into the BamHI site of the pKS336 vector (40). The 
LASV-NP gene that was inserted into the pKS336 vector, pKS336-LASV-NP, 
was confirmed to be in the correct orientation to the promoter, tested for 
nucleotide sequencing as described above, and the nucleotide sequence of the 
gene was confirmed to be identical to the original sequence. HeLa cells were 
then transfected with pKS336-LASV-NP by using a FuGENE6 transfection re­
agent (Roche Diagnostics) according to the manufacturer’s instructions. The 
cells transfected with the plasmid were selected with 3 pg of blasticidin S- 
hydrochloride/ml in MEM-10FBS. The HeLa cell clones were analyzed for the 
expression of LASV-rNP by UFA using the rabbit serum raised against His- 
LASV-rNP. The cells expressing LASV-rNP were subcloned and used as UFA 
antigens.
Ag-capture ELISA. Ag-capture ELISA was performed as previously described 
(32, 41). The purified MAb to His-LASV-rNP, MAb 4A5, produced in the 
present study was diluted in PBS solution, and 100 pl was adsorbed overnight at 
4°C onto the immunoplates (96-well type plate, Pro-Bind, Falcon; Becton Dick­
inson Labware). Purified MAb 4A5 was coated onto the immunoplates at a 
concentration of approximately 100 ng/well in 100 pl of PBS. The difference in 
the procedures between the Ag-capture ELISA in the present study and those in
FIG. 3. Staining patterns of LASV-rNP-expressing HeLa cells by 
sera from an LF patient (A) and a healthy control (B) in an UFA.
previous studies (32, 37, 41) is that the MAb, MAb 4A5, and rabbit serum raised 
to His-LASV-rNP were used as capture and detector antibodies, respectively. 
The procedure for the Ag-capture ELISA was performed as follows. The ELISA 
plate was coated with capture MAb, followed by blocking of the plate with 
M-T-PBS, addition of the samples to the ELISA plate, detection of the captured 
LASV-NP with rabbit serum raised to His-LASV-rNP, detection of rabbit IgG 
antibody that reacted with the captured antigen with goat anti-rabbit IgG anti­
bodies conjugated with HRPO (Zymed Laboratories), and substrate reaction. In 
each run of the Ag-capture ELISA, the negative control antigen (M-T-PBS) was 
also tested. Serially diluted samples were added to the MAb-coated wells. The 
OD405 values of each well were adjusted by subtracting the OD405 value of the 
negative control antigen from the corresponding well. The adjusted OD405 was 
taken as a measure of the amount of antigen specifically bound. All samples were 
treated with 1% Nonidet-P40 (NP-40) in PBS to destroy the LASV virion and 
expose the nucleoprotein in the LASV virion.
RT-PCR. RT-PCR was performed as previously described (10). The primers 
used in the RT-PCR were 36E2 (5'-ACCGGGGATCCTAGGCATT-3') and 
80F2 (5'-ATATAATGATGACTGTTGTTCTTTGTGCA-3'). The RT-PCR 
was carried out with a Ready-to-Go RT-PCR tube (Pharmacia). The amplified 
PCR products were visualized with ethidium bromide in 2% agarose gel after 
electrophoresis.
RESULTS
Expression of His-LASV-rNP. Tn5 cells infected with each 
of the recombinant baculoviruses—Ac-His-LASV-NP, Ac- 
LCMV-rNP, and Ac-JUNV-rNP—were suspended in PBS-2 
M urea. Most of the cell proteins were solubilized by this
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FIG. 4. Reactivity of antibodies to arenaviruses (LASV, LCMV, and JUNV) to the rNPs of these viruses. The reactivities of rabbit sera raised 
to LASV-rNP (•), LCMV-rNP (■), or JUNV-rNP (A) with the antigens His-LASV-rNP (A), LCMV-rNP (B), and JUNV-rNP (C) in an 
IgG-ELISA are shown. The reactivities of the sera collected from patients with LF (D) and AHF (E) with the antigens LASV-rNP (•), LCMV-rNP 
(■), and JUNV-rNP (A) and negative control antigen (♦) in an IgG-ELISA are also shown.
Dilution level [100, log2]
treatment, whereas the rNPs of these viruses remained insol­
uble. After centrifugation at 15,000 x g for 10 min, pellet 
fractions were collected. The rNPs, which were still present in 
the pellet fractions, were completely solubilized in PBS-8 M 
urea. The samples were then centrifuged at 15,000 x g for 10 
min, and the supernatant fractions of the PBS-8 M urea were 
confirmed to contain highly purified recombinant rNPs of 
arenaviruses (Fig. 2).
Development of indirect immunofluorescence. The LASV- 
rNP was expressed in HeLa cells by transfection with the ex­
pression vector, pKS336-LASV-NP. The transfected cells were 
stained by anti-His-LASV-rNP rabbit serum and human serum 
samples from LF patients (Fig. 3). All 4 serum samples col­
lected from two LF patients showed a positive staining, but 96 
control serum samples did not. The LASV-rNP-based UFA 
was also evaluated using serum samples collected from mon­
keys experimentally infected with LASV. All of the sera col­
lected from five LASV-infected monkeys showed a positive 
staining, but those from four mock-infected monkeys did not.
Development of His-LASV-rNP-based IgG-ELISA. Four se­
rum samples collected from LF patients were determined to be 
positive by His-LASV-rNP-based IgG-ELISA, whereas 94 of 
the 96 control serum samples were determined to be negative. 
Thus, the sensitivity and specificity of the ELISA were 100 and 
96%, respectively. All serum samples collected from five 
LASV-infected monkeys were determined to be positive, 
whereas those from four mock-infected monkeys were nega­
tive.
In order to examine cross-reactivity among arenaviruses in 
the LASV-rNP-based IgG-ELISA, antisera against LASV- 
rNP, LCMV-rNP, or JUNV-rNP were examined (Fig. 4). The 
anti-LASV-rNP serum showed a strongly positive reaction, and 
anti-LCMV rNP and anti-JUNV-rNP sera showed strongly 
positive reactions in the IgG ELISA using the respective anti­
gens (Fig. 4A, B, and C). Anti-LCMV-rNP and anti-JUNV- 
rNP sera showed a less strongly positive reaction in the His- 
LASV-rNP-based IgG-ELISA than anti-LASV-rNP serum 
(Fig. 4A). Anti-LASV-rNP and anti-JUNV-rNP also showed a 
less strongly positive reaction in the His-LCMV-rNP-based 
IgG-ELISA than anti-LCMV-rNP serum (Fig. 4B). However, 
anti-LASV-rNP and anti-LCMV-rNP sera showed a negative 
reaction in the JUNV-rNP-based IgG-ELISA (Fig. 4C). Hu­
man sera from LF patients showed a highly positive reaction in 
the LASV-rNP-based IgG-ELISA, but sera from patients with 
Argentine hemorrhagic fever (AHF), which is caused by 
JUNV, did not (Fig. 4D). Serum from an AHF patient showed 
a highly positive reaction in the JUNV-rNP-based IgG-ELISA 
(Fig. 4E). These results suggest that cross-reactive antibody 
among arenaviruses may be detected by the newly developed 
LASV-rNP-based IgG-ELISA.
Development of LASV Ag-capture ELISA. Three clones of a 
hybridoma that excreted an MAb to His-LASV-rNP were es-
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FIG. 5. Detection of the LASV genome by the RT-PCR (A), LASV-NP by the LASV-NP-Ag-capture ELISA (B), and the infectious dose of LASV 
(C) in serially collected sera of hamsters experimentally infected with LASV. The OD405 values in panel B were obtained at a dilution of 1:40.
tablished. The isotype of the three MAbs were identified as 
IgGl. These MAbs were designated MAb 4A5, MAb 6C11, 
and MAb 2-11. Of these MAbs, MAb 4A5 was the most effi­
cient in capturing His-LASV-rNP in the Ag-capture ELISA 
format. The Ag-capture ELISA with MAb 4A5 detected His- 
LASV-rNP concentrations as low as 800 pg/ml (data not 
shown). Furthermore, the Ag-capture ELISA detected the 
MOPV-NP but not the rNPs of LCMV and JUNV (data not 
shown).
All of the sera collected from five LASV-infected hamsters 
on days 11 and 16 postinfection were antigen positive in the 
Ag-capture ELISA using MAb 4A5 as a capture antibody, 
whereas the sera collected on days 0 and 4 were antigen neg­
ative. The OD405 values in the ELISA were highest on day 11. 
The reactivity patterns in each hamster in the ELISA were 
similar to the viremia levels (Fig. 5). The sera collected on days 
11 and 16 were found to be LASV genome positive by RT- 
PCR (10). Thus, the sensitivity of the Ag-capture ELISA was 
similar to that of the RT-PCR.
Determination of the epitope recognized by the monoclonal 
antibodies. The epitope recognized by MAbs was determined. 
MAb-4A5 reacted in Western blots with GST-LASV-rNPl-6 
(full-length LASV-rNP), GST-LASV-rNPl-5, and GST- 
LASV-rNPl-4 but not with the other truncated LASV-rNPs 
shown in Table 1, suggesting that MAb 4A5 reacted with a 
conformational epitope located on the amino-terminal portion 
of LASV-rNP. The epitope was maintained when the extreme 
amino-terminal portion, LASV-rNPl, was present but was lost 
when LASV-rNPl was removed. These results suggest that the 
extreme amino-terminal portion, LASV-rNPl, is essential for 
the maintenance of the conformational epitope. MAbs 6C11 
and 2-11 reacted in Western blots with GST-LASV-rNPl and 
GST-LASV-rNP5, respectively (Table 1).
The Pepscan analyses indicated that MAbs 6C11 and 2-11
TABLE 1. Reactivities of the MAbs developed in the present study 
with the GST-tagged truncated LASV-rNP in Western blot analyses
Truncated LASV-rNP
Reactivity with MAbT
6C11 4A5 2-11
LASV-rNPl +
LASV-rNP2 - - -
LASV-rNP3 - - -
LASV-rNP4 - - -
LASV-rNP5 - - +
LASV-rNP6 - - -
LASV-rNPl-2 ND - ND
LASV-rNPl-3 ND - ND
LASV-rNPl-4 ND + ND
LASV-rNPl-5 ND + ND
LASV-rNPl-66 ND + ND
LASV-rNP2-7 ND - ND
LASV-rNP3-6 ND - ND
LASV-rNP4-6 ND - ND
LASV-rNP5-6 ND - ND
" “+” and indicate positive and negative reactions, respectively. ND, not 
determined.
* LASV-rNPl-6 indicates LASV-rNP.
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TABLE 2. Reactivities of the MAbs developed in the present study 
with the NPs of LASV, MOPV, LCMV, and JUNV in 
Western blot analyses
MAb
Reactivity of MAb" with NP of:
LASV MOPV LCMV JUNV
4A5 + +
6C11 + ND + -
2-11 + ND -
a “+” and indicate positive and negative reactions, respectively. ND, not 
determined. The reactivities of MAb 6C11 and MAb 2-11 were not evaluated 
with MOPV-NP. However, theoretically, MAb 6C11 should be reactive with 
MOPV-NP due to the presence of the amino acid residues that can react with 
MAb 6C11, but MAb 2-11 should not react with MOPV-NP due to the absence 
of the amino acid residues that can react with MAb 2-11.
recognized linear epitopes. MAbs 6C-11 and 2-11 recognized 
GLDFSEV (aa 41 to 47) within LASV-rNPl and FATQP (aa 
439 to 443) within LASV-rNP5, respectively (Fig. 6). The re­
activity patterns of these MAbs with NPs of LASV, MOPV, 
LCMV, and JUNV are summarized in Table 2.
DISCUSSION
We report here the development of diagnostic systems (an­
tibody and antigen detection systems) for LF using LASV-rNP.
The LASV-rNP-based IgG-ELISA was sensitive and specific in 
detecting anti-LASV-IgG. Although the data were not shown, 
an IgM-capture ELISA using purified LASV-rNP as an anti­
gen was developed in the same way as that shown in previous 
reports and detected LASV-IgM antibody (42, 43). All sera 
collected from LF patients and monkeys infected with LASV 
showed positive reactions in the LASV-rNP-based UFA. The 
staining patterns of the rNP with these sera were granular in 
the UFA (Fig. 3), making it easy to distinguish positives from 
negatives. UFA using LASV-rNP-expressing HeLa cells was 
also highly sensitive and specific in detecting LAS V-IgG. In the 
preliminary study, ca. 15% of the sera collected from 334 
Ghanaians and only less than 1% of 280 Zambians showed 
positive reactions in the LASV-rNP-based IgG ELISA (our 
data). The results are considered to be compatible with the fact 
that LF is endemic to the western African region, including 
Ghana, but not to the eastern African region. The LASV-rNP- 
based antibody detection systems such as ELISA and UFA 
were suggested to be useful not only in the diagnosis of but also 
in the seroepidemiological study of LF.
The LASV-rNPs were expressed by a transformation system 
in E. coli or by recombinant baculovirus systems and have 
already been applied as antigens in ELISA, Western blotting, 
and UFA for the detection of antibodies to LASV (4, 14, 16, 
22, 23, 44). In the present study, an Ag-capture ELISA using
(A) (B)
44-DFSEVSNVQR
43-LDFSEVSNVQ
42-GLDFSEVSNV
41-HGLDFSEVSN
40-LHGLDFSEVS
39-LLHGLDFSEV
38-ALLHGLDFSE
37-QALLHGLDFS
p 
o CO
o c
E 
<
OD405 measured by ELISA
C
O.
CL
8c
c
I
OD405 measured by ELISA
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Amino acid sequence of the corresponding region
Arenavi rus-NP MoAb-6C11 MoAb-2-11
LASV-NP 31 -WKDAQALLHGLDFSEVNVQRLMRKERRD 431-HGIDVTDLFATQPGLTSAVI
MOPV-NP 31-VIKDAQALLHGLDFSEVANVQRLMRKEKRD 432-HGIDIQDLFSVQPGLTSAVI
LCMV-NP 31-VIKDATNLLNGLDFSEVSNVQRIMRKEKRD 424-HGMDLADLFNAQPGLTSSVI
JUNV-NP 31 -VLKDAKLIADSIDFNQVAQVQRALRKTKRG 422-HGILMKDIEDAMPGVLSYVI
FIG. 6. Pepscan analyses to determine the epitopes of MAb 6C11 (A) and MAb 2-11 (B). The vertical bar indicates the amino acid residues 
with an amino acid position within the LASV-NP. MAb 6C11 was confirmed to react with 7 aa residues positioned from aa 42 to 48 (GLDFSEV) 
within LASV-NP1. MoAb-2-11 was confirmed to react with 5 aa residues positioned from aa 439 to 443 (FATQP) within LASV-NP5. (C) The 
corresponding amino acid residues to the epitope of the MAb 6C11 and MAb 2-11 among MOPV, LCMV, and JUNV are shown. The GenBank 
accession numbers for the S genes of LASV, MOPV, LCMV, and JUNV are NC_004296, AY772170, AY847350, and DQ272266, respectively. The 
epitope of the MAb 6C11 is present not only in the nucleoprotein of LASV but also in those of MOPV and LCMV—but not in that of JUNV.
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MAbs to LASV-rNP was also developed. Furthermore, detec­
tion of the cross-reactive antibody by LASV-rNP-based IgG- 
ELISA was examined. The results for cross-reactivity indicate 
that the LASV-rNP-based IgG-ELISA detects not only anti­
bodies to LASV but also those to LCMV.
The Ag-capture ELISA using MAb 4A5 was confirmed to be 
useful in the detection of authentic LASV antigen in sera 
serially collected from hamsters infected with LASV. The sen­
sitivity of the MAb 4A5-based Ag-ELISA was similar to that of 
conventional RT-PCR, the efficiency of which in the diagnosis 
of LF was previously reported (10). Therefore, the MAb 4A5- 
based Ag-capture ELISA is regarded as useful in the diagnosis 
of LF. Unfortunately, the efficacy of the MAb 4A5-based Ag- 
capture ELISA in the diagnosis of LF was not evaluated using 
serum samples from patients. Thus, further study is still re­
quired. The three MAbs, including MAb 4A5, were character­
ized, and the corresponding amino acid residues within the 
nucleoproteins of LASV, MOPV, LCMV, and JUNV to the 
epitopes of MAb 6C11 and MAb 2-11 are summarized in Fig. 
6C. It was of interest that LASV, MOPV, LCMV, and JUNV 
might be identified by analyses of the reactivity patterns of 
MAbs 4A5, 6C11, and 2-11 to the nucleoproteins of each virus. 
The nucleoproteins of all LASV strains circulating in the west­
ern and central parts of Africa would be detected by the MAb 
4A5-based Ag-capture ELISA, since this ELISA was able to 
detect MOPV-NP that was different from LASV in terms of 
genetic and evolutional characteristics.
We have thus far reported the development of antibody and 
antigen detection systems using the recombinant nucleopro­
teins of the viruses for Ebola hemorrhagic fever, Marburg 
hemorrhagic fever, and Crimean-Congo hemorrhagic fever 
(32, 33, 36-42). Recently, a number of highly pathogenic 
emerging virus infections in humans appeared, such as Nipah 
virus encephalitis (8), SARS-coronavirus infections (21, 35), 
and highly pathogenic avian influenza virus infections (9, 45, 
46). The strategy shown here might be applicable to the de­
velopment of diagnostic systems for severe viral infections 
whose etiologic agents are highly pathogenic to humans as an 
alternative method to methods using infectious viruses.
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